Key Market Overview:
Pyelonephritis Treatment Market, valued at USD 251.65 Million in 2022, is expected to exhibit steady growth with a CAGR of 4.3% during the forecast period (2023-2030), the Pyelonephritis Treatment Market is projected to reach a value of USD 351.35 Million by 2030
Pyelonephritis occurs as a complication of an ascending urinary tract infection that spreads from the bladder to the kidneys. Symptoms of pyelonephritis disease usually include fever, flank pain, nausea, vomiting, burning with urination, increased frequency, and urgency. The healthcare provider prescribes various types of treatments such as plazomicin, levofloxacin, and others for the treatment of pyelonephritis. These treatments reduce the pain and reduce the adverse impact of pyelonephritis disease. The increasing prevalence of chronic kidney diseases is a prime factor accelerating the growth of the market.
For instance, according to the National Institute of Diabetes and Digestive and Kidney Diseases (NIH), in 2021, approximately 1 out of 7 people in the United States suffer from chronic kidney disease, which is about 37 million people in the country. Thus, the increasing prevalence of chronic kidney diseases is accelerating the demand for pyelonephritis treatments to ease the symptoms such as fever, nausea, voting, and others, in turn, driving the growth of nausea, voting, and others driving the growth of the market.
Pyelonephritis Treatment Report Coverage:
|Report Attributes||Report Details|
|Market Size in 2030 (USD Million)||351.35 Million|
|CAGR (2023-2030)||4.3 %|
|By Treatment Type||Plazomicin, Levofloxacin, Meropenem and Vaborbactam, and others|
|By End User||Hospitals, Homecare, Specialty Clinics, Others|
- Asia-Pacific [China, Southeast Asia, India, Japan, Korea, Western Asia]
- Europe [Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey]
- North America [United States, Canada, Mexico]
- Middle East & Africa [GCC, North Africa, South Africa]
- South America [Brazil, Argentina, Columbia, Chile, Peru]
|Key Players||Melinta Therapeutics LLC, Cipla Inc., Allecra Therapeutics, Pfizer Inc., Allergan, Spero Therapeutics, MerLion Pharmaceuticals GmbH, Merck & Co., Inc., Bayer AG, and Sanofi|
The pyelonephritis drugs prevent the progression of kidney infection. The pyelonephritis drugs can prevent mild cases of pyelonephritis in 2 to 3 days. For instance, according to the National Library of Medicine (NIH), in 2021, about 434.3 million people were suffering from chronic kidney disease. Across the Asian region such as southern, eastern, and south-eastern, most of the disease cases observed in India and China were 299.9 million. Thus, the increase in the cases of pyelonephritis is due to the factors such as weakened immune systems, changes in the urinary tract during pregnancy, and others. As a result, the demand for pyelonephritis is increasing to enable a reduction in the spreading of kidney infections, thereby boosting the market growth.
Pyelonephritis drugs have allergic reactions including, anaphylaxis, difficulty in breathing, drowsiness, and increased thirst, among others. For instance, according to the Mayo Foundation for Medical Education and Research (MFMER), Plazomicin, a medication used for the treatment of pyelonephritis can cause allergic effects such as itching, rash, trouble breathing, hoarseness, and others. Thus, the various allergic reactions related to pyelonephritis drugs is a major concern for patients and healthcare providers can limit the adoption of Pyelonephritis drugs. For this reason, adverse side effects associated with pyelonephritis drugs are posing a bottleneck for the demand of the market.
The increasing government partnerships with leading players dealing in pyelonephritis treatment, and others are some of the prominent factors prompting the global pyelonephritis treatment manufacturers to develop a new range of drugs. This factor is leading to the increasing pipeline for drugs for the treatment of pyelonephritis treatment. For instance, Pfizer Inc., a leading pharmaceutical manufacturer in the United States is developing CTB+AVP (PF-07612577), a therapy for the treatment of pyelonephritis. Thus, the increasing pipeline for the treatment of pyelonephritis drugs will create a potential growth opportunity for the market at the global level.
Pyelonephritis Treatment Market Segmentation:
By Treatment Type
The treatment type segment is classified into plazomicin, levofloxacin, meropenem and vaborbactam, and others. In 2022, the plazomicin segment accounted for the highest market share in the pyelonephritis treatment market. Plazomicin is utilized for the treatment of patients with pyelonephritis as it is effective against various bacteria-producing carbapenemases or other specific hydrolases. Furthermore, the utilization of plazomicin for the treatment of plazomicin achieves superior composite cure rates as compared with meropenem. For instance, according to the BMJ, a journal published by British Medical Association, in 2021, about 159.8 million people in China were suffering from chronic kidney diseases. Thus, the increasing number of kidney disease cases is accelerating the demand growth for plazomicin to kill bacteria, this, in turn, is propelling the growth of the market.
However, levofloxacin is expected to grow at the fastest CAGR during the forecast period due to the increasing research and development activities for the commercialization of levofloxacin.
By End Use
The end user segment is categorized into hospitals, homecare, specialty clinics, others. In 2022, hospitals segment accounted for the highest market share in the pyelonephritis treatment market. In hospitals, the utilization of pyelonephritis treatment enables reduce in the number of recurrent urinary tract infections (UTIs). For instance, in March 2021, Gurdwara Management Committee opened the Guru Harikshan Institute of Medical Sciences and Research Kidney Dialysis Hospital in India for the treatment of kidney infections. Hence, the increasing launch of pyelonephritis treatment hospitals to reduce the spread of pyelonephritis among patients is fostering market growth.
However, the homecare segment is expected to be the fastest-growing segment over the forecast period owing to the increasing adoption of pyelonephritis treatment so that patients can conveniently consult with doctors and get their medications easily.
By region, the market is segmented into North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America. In 2022, North Ameirca accounted for the highest market share in the pyelonephritis treatment market due to the increasing development of a new range of pyelonephritis. For instance, in January 2022, Spero Therapeutics, Inc., announced the FDA approval for the tebipenem HBr oral tablets for the efficient treatment of complicated urinary tract infections (UTIs), including pyelonephritis. Thus, the increasing FDA approvals for the treatment of pyelonephritis in the North American region will boost the commercialization of pyelonephritis treatments in the upcoming years, thereby propelling the growth of the market.
Nevertheless, Asia Pacific is expected to be the fastest-growing region over the forecast period due to the presence of major players in the market, the development of new healthcare facilities for the treatment of pyelonephritis, and others.
Pyelonephritis Treatment Market Competitive Landscape:
The pyelonephritis treatment market is highly competitive, with several large players and numerous small and medium-sized enterprises. These companies have strong research and development capabilities and a strong presence in the market through their extensive product portfolios and distribution networks. The market is characterized by intense competition, with companies focusing on expanding their product offerings and increasing their market share through mergers, acquisitions, and partnerships. The key players in the market include-
• Melinta Therapeutics LLC
• Cipla Inc.
• Allecra Therapeutics
• Pfizer Inc.
• Spero Therapeutics
• MerLion Pharmaceuticals GmbH
• Merck & Co., Inc.
• Bayer AG
• In September 2022, Spero Therapeutics and GSK formed an exclusive license agreement for tebipenem HBr, a late-stage antibiotic for the treatment of pyelonephritis. Thus, the increasing licensing will accelerate the product offering of pyelonephritis drug treatments at the global level in the upcoming years.